Vanguard Group Inc. Purchases 14,535 Shares of IDEAYA Biosciences, Inc. $IDYA

Vanguard Group Inc. boosted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 0.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,092,619 shares of the company’s stock after purchasing an additional 14,535 shares during the quarter. Vanguard Group Inc. owned approximately 5.81% of IDEAYA Biosciences worth $83,417,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Mariner LLC lifted its holdings in shares of IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company’s stock valued at $251,000 after purchasing an additional 869 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in IDEAYA Biosciences by 6.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company’s stock valued at $349,000 after buying an additional 1,214 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock valued at $39,000 after buying an additional 1,546 shares during the last quarter. CWM LLC boosted its holdings in IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after acquiring an additional 1,814 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in IDEAYA Biosciences in the fourth quarter worth $47,000. Institutional investors own 98.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IDYA. The Goldman Sachs Group raised IDEAYA Biosciences to a “hold” rating and set a $25.00 price target for the company in a research report on Thursday, July 10th. Wells Fargo & Company started coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They issued an “overweight” rating and a $44.00 target price for the company. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an “outperform” rating to a “moderate buy” rating and dropped their target price for the stock from $57.00 to $30.00 in a research note on Wednesday, July 9th. TD Cowen initiated coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a “buy” rating for the company. Finally, JPMorgan Chase & Co. upped their price objective on IDEAYA Biosciences from $66.00 to $72.00 and gave the company an “overweight” rating in a research report on Monday, July 28th. Ten investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $48.09.

IDEAYA Biosciences Trading Up 2.0%

NASDAQ:IDYA opened at $25.12 on Friday. The company has a market cap of $2.20 billion, a PE ratio of -6.63 and a beta of 0.09. The company has a 50 day simple moving average of $22.98 and a two-hundred day simple moving average of $20.38. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $40.74.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $3.48 million. During the same quarter last year, the firm earned ($0.68) earnings per share. IDEAYA Biosciences’s revenue for the quarter was up NaN% on a year-over-year basis. Research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.